Liquidia (NASDAQ: LQDA) recently received a number of ratings updates from brokerages and research firms:
- 11/13/2026 – Liquidia is now covered by HC Wainwright. They set a “buy” rating and a $76.00 price target on the stock.
- 11/12/2026 – Liquidia was upgraded by Zacks Research from “strong sell” to “hold”.
- 11/11/2026 – Liquidia was given a new $54.00 price target by Bank of America. They now have a “neutral” rating on the stock.
- 11/11/2026 – Liquidia had its price target raised by Wells Fargo & Company from $33.00 to $40.00. They now have an “equal weight” rating on the stock.
- 11/11/2026 – Liquidia was upgraded by Raymond James Financial from “outperform” to “strong-buy”. They now have a $77.00 price target on the stock, up from $53.00.
- 11/11/2026 – Liquidia had its price target raised by Needham & Company LLC from $58.00 to $66.00. They now have a “buy” rating on the stock.
- 11/10/2026 – Liquidia had its price target raised by Jefferies Financial Group from $55.00 to $62.00. They now have a “buy” rating on the stock.
- 11/10/2026 – Liquidia had its price target raised by BTIG Research from $70.00 to $87.00. They now have a “buy” rating on the stock.
- 10/15/2026 – Liquidia was given a new $65.00 price target by Royal Bank Of Canada.
- 10/15/2026 – Liquidia had its price target raised by HC Wainwright from $58.00 to $65.00. They now have a “buy” rating on the stock.
- 10/14/2026 – Liquidia had its price target raised by Wells Fargo & Company from $30.00 to $33.00. They now have an “equal weight” rating on the stock.
- 10/14/2026 – Liquidia was upgraded by Lifesci Capital from “hold” to “outperform”. They now have a $59.00 price target on the stock.
- 10/14/2026 – Liquidia was upgraded by BTIG Research from “neutral” to “buy”. They now have a $70.00 price target on the stock.
- 10/14/2026 – Liquidia had its price target lowered by Needham & Company LLC from $72.00 to $58.00. They now have a “buy” rating on the stock.
- 10/8/2026 – Liquidia had its “outperform” rating reaffirmed by Raymond James Financial.
- 10/3/2026 – Liquidia was downgraded by Wall Street Zen from “buy” to “hold”.
- 10/2/2026 – Liquidia was given a new $58.00 price target by Wedbush.
- 10/2/2026 – Liquidia was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $30.00 price target on the stock, down from $108.00.
- 10/2/2026 – Liquidia had its price target lowered by HC Wainwright from $130.00 to $58.00. They now have a “buy” rating on the stock.
- 10/1/2026 – Liquidia was downgraded by Raymond James Financial from “strong-buy” to “outperform”. They now have a $53.00 price target on the stock, down from $106.00.
- 10/1/2026 – Liquidia had its “neutral” rating reaffirmed by Citigroup.
- 10/1/2026 – Liquidia was downgraded by BTIG Research from “buy” to “neutral”.
- 10/1/2026 – Liquidia was downgraded by Wells Fargo & Company from “overweight” to “equal weight”. They now have a $30.00 price target on the stock, down from $108.00.
- 10/1/2026 – Liquidia was upgraded by Jefferies Financial Group to “strong-buy”.
- 10/1/2026 – Liquidia had its price target lowered by Needham & Company LLC from $110.00 to $72.00. They now have a “buy” rating on the stock.
- 9/22/2026 – Liquidia was upgraded by Weiss Ratings from “sell (d-)” to “hold (c)”.
- 9/22/2026 – Liquidia was downgraded by Zacks Research from “hold” to “strong sell”.
Liquidia Stock Down 3.9%
Shares of LQDA stock traded down $2.20 during mid-day trading on Friday, hitting $54.43. The company’s stock had a trading volume of 1,690,881 shares, compared to its average volume of 2,285,929. Liquidia Corporation has a 52-week low of $22.31 and a 52-week high of $93.61. The business has a 50-day moving average price of $48.02 and a 200 day moving average price of $55.03. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.96 and a current ratio of 1.02. The stock has a market cap of $4.90 billion, a price-to-earnings ratio of -44.25 and a beta of 0.40.
Liquidia (NASDAQ:LQDA – Get Free Report) last announced its quarterly earnings results on Tuesday, November 10th. The company reported ($2.64) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.96 by ($3.60). Liquidia had a negative net margin of 15.15% and a positive return on equity of 264.65%. The business had revenue of $225.30 million for the quarter, compared to the consensus estimate of $214.18 million. During the same period in the previous year, the company earned ($0.04) earnings per share. The company’s revenue for the quarter was up 314.9% compared to the same quarter last year. Research analysts predict that Liquidia Corporation will post 3.36 EPS for the current fiscal year.
Insider Buying and Selling at Liquidia
In other news, General Counsel Russell Schundler sold 13,692 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $389,948.16. Following the completion of the transaction, the general counsel directly owned 602,841 shares of the company’s stock, valued at $17,168,911.68. The trade was a 2.22% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Roger Jeffs sold 32,744 shares of the business’s stock in a transaction that occurred on Monday, October 12th. The shares were sold at an average price of $28.48, for a total transaction of $932,549.12. Following the transaction, the chief executive officer directly owned 1,125,848 shares of the company’s stock, valued at $32,064,151.04. The trade was a 2.83% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 358,232 shares of company stock worth $10,599,228. 25.60% of the stock is owned by company insiders.
Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing treatments for pulmonary hypertension and other serious diseases. Its work includes inhaled therapies designed to deliver medicines to the lungs. The company’s marketed product, Yutrepia (treprostinil) inhalation powder, is approved in the United States for adults with pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Liquidia also has a pipeline of investigational therapies, including other formulations of treprostinil.
Read More
- Five stocks we like better than Liquidia
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Liquidia Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
